← Eichor
Condition: Herpesviridae Infections Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Herpesviridae Infections

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06793241AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Phase 1/Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT05480449Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acut
Phase 1/Phase 2 · 13 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05310591Recommendations for the Treatment of Children With Burkitt's Lymphoma
Phase N/A · 7 location(s) · French Africa Pediatric Oncology Group · NCT04425421Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-R
Phase 1/Phase 2 · 1 location(s) · Liping Dou · NCT07575971Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT06119256Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Long-term Follow up Local Registry Study of Kymriah in South Korea
Phase N/A · 16 location(s) · Novartis Pharmaceuticals · NCT06785818CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Cent
NA · 1 location(s) · National Taiwan University Hospital · NCT07294547Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07066982Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06287229Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07329686Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05333302Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Rel
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06058858A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rub
Phase 3 · 22 location(s) · GlaxoSmithKline · NCT06855160Natural History Study of GATA2 Deficiency and Related Disorders
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01905826Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunoco
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01011712AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
Phase 1/Phase 2 · 1 location(s) · Sinovac Biotech Co., Ltd · NCT07400003Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Phase 1/Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07069699Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/Phase 2 · 1 location(s) · Kara Yakhteh Tajhiz Azma Company · NCT06635330R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Phase 1 · 1 location(s) · Columbia University · NCT06926894Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.